OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

ALK-rearranged non-small-cell lung cancer: Ceritinib is highly active


Non–small-cell lung cancer ( NSCLC ) harboring the anaplastic lymphoma kinase gene ( ALK ) rearrangement is sensitive to the ALK inhibitor Crizotinib ( Xalkori ), but resistance invariably develops.
Ceritinib ( LDK378; Zykadia ) is a new ALK inhibitor that has shown greater antitumor potency than Crizotinib in preclinical studies.

In this phase 1 study, researchers have administered oral Ceritinib in doses of 50 to 750 mg once daily to patients with advanced cancers harboring genetic alterations in ALK.
In an expansion phase of the study, patients received the maximum tolerated dose.
Patients were assessed to determine the safety, pharmacokinetic properties, and antitumor activity of ceritinib.
Tumor biopsies were performed before Ceritinib treatment to identify resistance mutations in ALK in a group of patients with NSCLC who had had disease progression during treatment with Crizotinib.

A total of 59 patients were enrolled in the dose-escalation phase. The maximum tolerated dose of Ceritinib was 750 mg once daily; dose-limiting toxic events included diarrhea, vomiting, dehydration, elevated aminotransferase levels, and hypophosphatemia.

This phase was followed by an expansion phase, in which an additional 71 patients were treated, for a total of 130 patients overall.

Among 114 patients with non-small-cell lung cancer who received at least 400 mg of Ceritinib per day, the overall response rate was 58%.

Among 80 patients who had received Crizotinib previously, the response rate was 56%.

Responses were observed in patients with various resistance mutations in ALK and in patients without detectable mutations.

Among patients with non-small-cell lung cancer who received at least 400 mg of Ceritinib per day, the median progression-free survival was 7.0 months.

In conclusion, Ceritinib was highly active in patients with advanced, ALK-rearranged non–small-cell lung cancer, including those who had had disease progression during Crizotinib treatment, regardless of the presence of resistance mutations in ALK. ( Xagena )

Shaw AT et al, N Engl J Med 2014; 370:1189-1197

XagenaMedicine_2014



Indietro